Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

My-K Labs' founder Kun Chae Bae

Executive Summary

Pleaded guilty on April 20 in Baltimore Federal Court to one count of making illegal payments totaling $30,000 to former FDA Division of Generic Drugs Branch Chief Charles Chang, and to one count of providing a $500 gift certificate for a department store, a video cassette recorder, and two trips to Chicago to Joseph Maselli, a buyer for the Medical Directorate at the Defense Personnel Support Center in Philadelphia. Bae was charged on April 12 to one count of interstate travel in aid of racketeering in connection with one payment of $10,000 to Chang ("The Pink Sheet" April 16, T&G-1). Bae faces maximum penalties of five years incarceration and a $250,000 fine on the racketeering charge and two years in jail and a 250,000 fine on the gratuities charge.

You may also be interested in...



Calls to End Industry’s ‘Financial Entanglement’ With Healthcare Players

Financial ties between companies and healthcare bodies distort the production and use of evidence, claims a paper co-authored by researchers, clinicians and decision makers, including a representative of Germany’s HTA body, IQWiG.

Finland's Forendo Attracts Big Pharma For Liver Disease R&D

Turku, Finland-based Forendo Pharma has entered into a license and collaboration deal with Novartis involving the identification of novel drugs to treat chronic liver diseases.


 

Decision Time For MSD/AZ, Lilly, Kite EU Fast-Track Hopes

Three accelerated assessment requests will either be granted or rejected this week at the European Medicines Agency.

UsernamePublicRestriction

Register

PS017302

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel